ARMO News
Archived Headlines
- January IPOs raise $9 billion in record-breaking start to 2018 02/01/18
- Cancer biotech ARMO BioSciences prices upsized IPO above the range at $17 01/26/18
- US IPO Week Ahead: 10 IPOs expected to price, led by PagSeguro's $1.8 billion deal 01/19/18
- Immuno-oncology biotech ARMO Biosciences sets terms for $100 million IPO 01/16/18
- US IPO Week Ahead: ADT looks to secure $2 billion in 3-IPO week 01/12/18
See more
A Novel Idea: Biotechs with Innovative Therapies Outperform
Biotech IPOs offer investors a shot at exceptional returns but are often tricky for non-biochemists, which means most investors, to decipher. So we reviewed 2018’s biotech, asking a basic question: are they developing innovative approaches to disease...read more
What 2018’s IPOs Tell Us About 2H18
Performance of IPOs priced year to date may provide direction for the rest of the year. Through May 31, 76 IPOs have priced producing returns of 24% from the IPO price, mostly from the first day pop. Fully 57% of the IPOs have been in the ...read more
Biotechs take the podium with the year's 3 best IPOs
Biotechs hold gold, silver and bronze in the 2018 IPO market. Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech...read more
US IPO Week Ahead: Look for a wave of filings in a quiet holiday week with 2 IPOs
Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move...read more